| Literature DB >> 32316402 |
Larisa Ivanova1, Mati Karelson1, Dimitar A Dobchev1.
Abstract
Alzheimer's disease is a neurodegenerative condition for which currently there are no drugs that can cure its devastating impact on human brain function. Although there are therapeutics that are being used in contemporary medicine for treatment against Alzheimer's disease, new and more effective drugs are in great demand. In this work, we proposed three potential drug candidates which may act as multifunctional compounds simultaneously toward AChE, SERT, BACE1 and GSK3β protein targets. These candidates were discovered by using state-of-the-art methods as molecular calculations (molecular docking and molecular dynamics), artificial neural networks and multilinear regression models. These methods were used for virtual screening of the publicly available library containing more than twenty thousand compounds. The experimental testing enabled us to confirm a multitarget drug candidate active at low micromolar concentrations against two targets, e.g., AChE and BACE1.Entities:
Keywords: Alzheimer’s disease; CADD; QSAR; molecular docking; molecular dynamics; multifunctional drugs; neural networks
Year: 2020 PMID: 32316402 PMCID: PMC7221701 DOI: 10.3390/molecules25081846
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Figure 1General workflow of the computational studies.
Statistical parameters of the BMLR models for all four data sets.
| AChE BMLR Model—Log (IC50) = D0 + ∑(Bi ± ErrorsBi)*Di | |||||
|---|---|---|---|---|---|
| N = 239, R2 = 0.932026, R2cv = 0.929713, R2abc = 0.929519, s2 = 0.0808643, F = 802.121 | |||||
| Descriptor Di | Bi | Errors Bi | ti-Statistics | Descriptors | |
| 0 | 2.880 | 0.051 | 56.989 | Intercept | |
| 1 | 0.312 | 0.008 | 38.327 | Lowest resonance energy (AM1) for N–S bonds | |
| 2 | −2.475 | 0.184 | −13.462 | Max net atomic charge (AM1) for O atoms | |
| 3 | 0.174 | 0.009 | 19.494 | Final heat of formation (AM1)/# atoms | |
| 4 | −0.014 | 0.001 | −14.213 | Highest e-e repulsion (AM1) for N–H bonds | |
|
| |||||
| (AB,C): R2ab = | 0.923 | R2ab_cv = | 0.919 | R2c_pred = | 0.944 |
| (BC,A): R2bc = | 0.932 | R2bc_cv = | 0.929 | R2a_pred = | 0.930 |
| (CA,B): R2ca = | 0.938 | R2ca_cv = | 0.935 | R2b_pred = | 0.915 |
|
| |||||
| X-scrambling R2 = | 0.0170677 | ||||
| Y-scrambling R2 = | 0.0170352 | ||||
| XY-scrambling R2 = | 0.0175535 | ||||
|
| |||||
|
| |||||
| 0 | 23.461 | 0.735 | 31.898 | Intercept | |
| 1 | 0.001 | 0.000 | 10.494 | PPSA2 Total charge weighted PPSA (AM1) | |
| 2 | −0.182 | 0.003 | −55.132 | Structural Information content (order 2) | |
| 3 | −4.527 | 0.217 | −20.886 | Average valency (AM1) | |
| 4 | −2.230 | 0.129 | −17.320 | Balaban index | |
|
| |||||
| (AB,C): R2ab = | 0.905 | R2ab_cv = | 0.901 | R2c_pred = | 0.909 |
| (BC,A): R2bc = | 0.912 | R2bc_cv = | 0.908 | R2a_pred = | 0.897 |
| (CA,B): R2ca = | 0.908 | R2ca_cv = | 0.904 | R2b_pred = | 0.905 |
|
| |||||
| X-scrambling R2 = | 0.0106888 | ||||
| Y-scrambling R2 = | 0.0106174 | ||||
| XY-scrambling R2 = | 0.0110244 | ||||
|
| |||||
|
| |||||
| 0 | 6.432 | 0.142 | 45.152 | Intercept | |
| 1 | −0.593 | 0.017 | −34.239 | HA dependent HDCA-2 (AM1) | |
| 2 | 1.569 | 0.058 | 27.210 | LUMO energy (AM1) | |
| 3 | 0.710 | 0.036 | 19.703 | HACA-2 (Zefirov) | |
| 4 | 11.621 | 0.694 | 16.746 | Min net atomic charge (Zefirov) for any atom type | |
|
| |||||
| (AB,C): R2ab = | 0.902 | R2ab_cv = | 0.896 | R2c_pred = | 0.899 |
| (BC,A): R2bc = | 0.900 | R2bc_cv = | 0.893 | R2a_pred = | 0.896 |
| (CA,B): R2ca = | 0.894 | R2ca_cv = | 0.887 | R2b_pred = | 0.907 |
|
| |||||
| X-scrambling R2 = | 0.0181116 | ||||
| Y-scrambling R2 = | 0.0171723 | ||||
| XY-scrambling R2 = | 0.0173102 | ||||
|
| |||||
|
| |||||
| 0 | 154.961 | 10.036 | 15.440 | Intercept | |
| 1 | 0.598 | 0.021 | 27.881 | Kier shape index (order 3) | |
| 2 | −3.882 | 0.255 | −15.202 | Lowest n-n repulsion (AM1) | |
| 3 | −0.119 | 0.005 | −22.512 | Bonding Information content (order 1) | |
| 4 | 7.575 | 0.452 | 16.740 | FHASA Fractional HASA (HASA/TMSA) (AM1) | |
|
| |||||
| (AB,C): R2ab = | 0.839 | R2ab_cv = | 0.826 | R2c_pred = | 0.857 |
| (BC,A): R2bc = | 0.839 | R2bc_cv = | 0.827 | R2a_pred = | 0.833 |
| (CA,B): R2ca = | 0.852 | R2ca_cv = | 0.840 | R2b_pred = | 0.843 |
|
| |||||
| X-scrambling R2 = | 0.018852 | ||||
| Y-scrambling R2 = | 0.0190767 | ||||
| XY-scrambling R2 = | 0.0183609 | ||||
Figure 2Scatter plots between experimental and predicted log (IC50) values for all BMLR models.
Figure 3Scatter plots between predicted and experimental log (IC50) values for all ANN models. Legend: training datapoints—blue triangles; validation datapoints—red dots.
The range of the predicted log (IC50) of the selected compounds for all target proteins.
| Target | Predicted Log (IC50) (nM) | |||
|---|---|---|---|---|
| ANN | MLR | |||
| min | max | min | max | |
| AChE | 1.975 | 3.882 | 3.407 | 4.082 |
| BACE1 | 3.149 | 3.958 | 2.452 | 5.280 |
| GSK3β | 2.385 | 4.166 | 1.548 | 9.760 |
| SERT | 0.567 | 1.737 | −0.770 | 3.799 |
Figure 4Structures of the selected compounds for biological experiments.
Figure 5Calculated binding modes of compound ZINC4027357 (A) in the active site of AChE (ID: 4EY6); (B) in the active site of BACE1 (ID: 6EQM); (C) in the active site of GSK3β (ID: 1PYX); (D) in the central active site of SERT (ID: 5I6X). The amino acid residues of target proteins are colored as gray (carbon), blue (nitrogen), red (oxygen), and white (hydrogen). Hydrogen bonds formed between compound and residues of target proteins are represented by green dashed lines, and pi–pi stacking is represented by a blue dashed line.
Calculated binding energies (kcal/mol) and binding modes of selected small-molecule ligands and known inhibitors to target proteins (AChE, BACE1, GSK3β and SERT).
| Compound | Binding Energy, ∆G, kcal/mol | Ligand Efficiency | Compound | Binding Energy, ∆G, kcal/mol | Ligand Efficiency |
|---|---|---|---|---|---|
|
|
| ||||
| (−)-huperzine A | −7.9 | 0.44 | 2WF | −7.1 | 0.32 |
| galantamine | −4.9 | 0.23 | BRD0209 | −6.9 | 0.27 |
| donepezil (DPZ) | −10.2 | 0.36 | PF-04802367 | −6.9 | 0.28 |
| ZINC1034491 | −9.8 | 0.47 | ZINC1034491 | −8.7 | 0.41 |
| ZINC4027357 | −9.3 | 0.44 | ZINC4027357 | −8.6 | 0.41 |
| ZINC3977996 | −9.2 | 0.44 | ZINC3977996 | −9.1 | 0.43 |
| ZINC1763229 | −9.2 | 0.46 | ZINC1763229 | −8.0 | 0.40 |
| ZINC1801081 | −9.1 | 0.46 | ZINC1801081 | −8.1 | 0.41 |
|
|
| ||||
| CNP520 | −10.7 | 0.31 | Paroxetine | −10.8 | 0.45 |
| VTI | −9.9 | 0.34 | S-citalopram | −9.5 | 0.39 |
| NVP-BXD552 | −9.2 | 0.23 | sertraline | −9.1 | 0.46 |
| ZINC1034491 | −10.0 | 0.48 | ZINC1034491 | −10.3 | 0.49 |
| ZINC4027357 | −10.0 | 0.48 | ZINC4027357 | −10.3 | 0.49 |
| ZINC3977996 | −10.2 | 0.49 | ZINC3977996 | −10.1 | 0.48 |
| ZINC1763229 | −8.9 | 0.45 | ZINC1763229 | −8.9 | 0.44 |
| ZINC1801081 | −9.6 | 0.48 | ZINC1801081 | −8.8 | 0.44 |
Figure 62D summary diagram of molecular dynamics calculated contacts between AChE and small-molecule ligands (A) ZINC3977996, (B) ZINC1034491 and (C) ZINC4027357. Interactions that occur more than 10% of the simulation time are shown.
Figure 72D summary diagram of molecular dynamics calculated contacts between BACE1 and small-molecule ligands (A) ZINC3977996, (B) ZINC1034491 and (C) ZINC4027357. Interactions that occur more than 10% of the simulation time are shown.
Figure 82D summary diagram of molecular dynamics calculated contacts between GSK3β and small-molecule ligands (A) ZINC3977996, (B) ZINC1034491 and (C) ZINC4027357. Interactions that occur more than 10% of the simulation time are shown.
Figure 92D summary diagram of molecular dynamics calculated contacts between SERT and small-molecule ligands (A) ZINC3977996, (B) ZINC1034491 and (C) ZINC4027357. Interactions that occur more than 10% of the simulation time are shown.